Novo Nordisk A/S (NYSE:NVO)’s Wegovy garnered the Food and Drug Administration’s approval for expanded use Friday, marking what the drugmaker said is a pivotal turn in the treatment landscape for individuals grappling with the dual challenges of obesity and established cardiovascular disease.
This approval underscores a new era in preventive health strategies, targeting a significant reduction in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attacks (myocardial infarction) and nonfatal strokes.
Leap Forward In Cardiovascular, Weight Management Therapy
The FDA’s green light is anchored in the …